New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
JAMA Medical NewsShow Notes
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more.
Related Content: A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026
More from JAMA Medical News
JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?"
JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss "Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain."
JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss 1 in 5 Children Report Using AI for Emotional Support--Is It Good News or Bad?
JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Remove the Fallopian Tubes If the Opportunity Arises, ACOG Says in New Ovarian Cancer Prevention Guidance."
JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "As More Adults Seek ADHD Care, Primary Care Clinicians Are Tasked With Getting the Diagnosis Right."